Cytokinetics Inc
CYTK
ISIN US23282W6057 / Valor 21533074
Cytokinetics Inc
UMushroom community rating:
About company
Cytokinetics Inc. is a biopharmaceutical company with a specialized focus on the development of innovative therapies aimed at enhancing muscle function for individuals suffering from debilitating diseases where muscle performance is compromised. Established over 25 years ago in South San Francisco, California, the company has carved a niche in muscle biology, pioneering the discovery, development, and commercialization of muscle activators and inhibitors. These novel therapeutic agents are designed as potential treatments for a range of serious conditions affecting muscle health. Under the leadership of experienced industry professionals, Cytokinetics has made significant strides in scientific research, evidenced by its extensive portfolio of over 115 scientific publications, participation in more than 100 clinical trials, and the securing of numerous patents. The company's commitment to advancing muscle biology research extends to its active engagement with the healthcare and scientific communities through peer-reviewed journals and medical forums, aiming to contribute meaningfully to patient care and medical knowledge.
Summarized from source with an LLMView SourceSector: TechnologyLatest Results (25.12.2024):
Cash Position
As of September 30, 2024, Cytokinetics Inc. reported having approximately $1.3 billion in cash, cash equivalents, and investments. This represents a decline of about $81 million from the $1.4 billion reported at the end of the second quarter of 2024.
Revenue
Cytokinetics Inc. recorded total revenues of $0.5 million for the third quarter of 2024. This is a slight increase compared to the $0.4 million in revenue reported for the same period in 2023.
Research and Development Expenses
For the third quarter of 2024, Cytokinetics Inc. reported research and development expenses of $84.6 million. This includes $11.4 million of non-cash stock-based compensation expense, compared to $82.5 million in the third quarter of 2023, which included $8.2 million of non-cash stock-based compensation expense.
General and Administrative Expenses
During the third quarter of 2024, Cytokinetics Inc. incurred general and administrative expenses totaling $56.7 million. This figure includes $13.9 million of non-cash stock-based compensation expense, up from $40.1 million in the same quarter of 2023, which included $10.5 million in non-cash stock-based compensation expense.
Net Loss
Cytokinetics Inc. reported a net loss of $160.5 million for the third quarter of 2024, translating to a loss of $(1.36) per share, both basic and diluted. This compares to a net loss of $129.4 million, or $(1.35) per share, basic and diluted, for the same period in 2023.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
5589 M
Market cap (USD)
1,337,109
Daily traded volume (Shares)
47.775 / 46.6
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
